Identified potential targets upregulated in RCC, such as MUC1, AXL, EGFR, C-MET, PD-L1, VEGF, HIF, etc., could be targeted in combination with targeting PAX, offering valuable support in the development of potential therapeutic strategies for RCC [134,135,136,137,138]. This evidence concerns the gene AXL and renal cell carcinoma.